Skip to main content

Advertisement

SpringerLink
Log in

Prophylaxis for chronic daily headache and chronic migraine with neuronal stabilizing agents

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Approaches to acute and prophylactic migraine and headache treatment are evolving as our understanding of some of the underlying pathophysiology improves. This article focuses on the emerging use of medications originally introduced for the treatment of seizures (anticonvulsants) as primary therapy for eradicating or reducing migraine and chronic daily headaches. A more accurate term for their pharmacologic mechanisms, if they are used to treat headaches and pain disorders, is neuromodulating or neuronal stabilizing agents. This term refers to their many cellular actions to reduce pain transmission supraspinally, in the spinal cord, and in the brainstem.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. FM Cutrer: Pain-sensitive cranial structures: chemical anatomy. In Wolff’s Headache and Other Head Pain, edn 7. Edited by Silberstein SD, Lipton RB, Dalessio DJ. New York: Oxford Press; 2001:50–56.

    Google Scholar 

  2. PJ Goadsby: Pathophysiology of headache. In Wolff’s Headache and Other Head Pain, edn 7. Edited by Silberstein SD, Lipton RB, Dalessio DJ. New York: Oxford Press; 2001:57–72.

    Google Scholar 

  3. RK Cady, RB Lipton, Hall C, Stewart WF, et al.: Treatment of mild migraine in disabled migraine sufferers: results of the Spectrum Study. Headache 2000, 40:792–797.

    Article  Google Scholar 

  4. Burstein R, Yarnitsky D, Goor-Aryeh I, et al.: An association between migraine and cutaneous allodynia. Ann Neurol 2000, 47:614–624.

    Article  PubMed  CAS  Google Scholar 

  5. Burstein R, Cutrer MF, Yarnitsky D: The development of cutaneous allodynia during a migraine attack: clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000, 123:1703–1709.

    Article  PubMed  Google Scholar 

  6. Fields HL, Busbaum AI: Central nervous system mechanisms of pain modulation. In Textbook of Pain, edn 4. Edited by Wall PD, Melzack R. London: Churchill Livingstone; 1999.

    Google Scholar 

  7. Silberstein SD, Lipton RB: Chronic daily headache, including transformed migraine, chronic tension tension-type headache, and medication overuse. In Wolff’s Headache and Other Head Pain, edn 7. Edited by Silberstein SD, Lipton RB, Dalessio DJ. New York: Oxford University Press; 2001:247–282.

    Google Scholar 

  8. Mathew NT, Saper JR, Silberstein SD, et al.: Migraine prophylaxis with divalproex. Arch Neurol 1995, 52:281–286.

    PubMed  CAS  Google Scholar 

  9. Rothrock JF, Kelly NM, Brody ML, Golbeck A: A differential response to treatment with divalproex sodium in patients with intractable headache. Cephalalgia 1994, 14:241–244.

    Article  PubMed  CAS  Google Scholar 

  10. Kaniecki RG: A comparison of divalproex with propranolol and placebo for the prophylaxis of migraine without aura. Arch Neurol 1997, 54:1141–1145.

    PubMed  CAS  Google Scholar 

  11. Silberstein SD, Collins SD: Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Headache 1999, 39:633–643.

    Article  PubMed  CAS  Google Scholar 

  12. Edwards K, Santarcangelo V, Shea P, Edward J: Intravenous valproate for acute treatment of migraine headaches [abstract]. Cephalalgia 1999, 19:356.

    Google Scholar 

  13. Krusz JC, Scott VB, Belanger J: Intravenous valproate sodium as a rapid and effective treatment for intractable migraines in the headache clinic [abstract]. Headache Q 2000, 11:56–57.

    Google Scholar 

  14. Mathew NT, Kailasam J, Meadors L, et al.: Intravenous valproate sodium (Depacon) aborts migraines rapidly: a preliminary report. Cephalalgia 1999, 19:73.

    Article  Google Scholar 

  15. Krusz JC: Intravenous valproate sodium in the treatment of migraine headaches in the headache clinic. Headache Q 2001, 12:39–41. Because potentially millions of visits to emergency departments for migraine occur yearly, we are in need of new intravenous treatments for intractable migraines. This study indicates new directions using neuronal stabilizing agents.

    Google Scholar 

  16. Robbins LR: Intravenous sodium valproate injection for prolonged migraine headache. Am J Pain Manage 2001, 11:5–7.

    Google Scholar 

  17. Karpitskiy VV, Schwartz TH, Gurnett CA, et al.: Intravenous valproate in the treatment of chronic daily headache. Cephalalgia 2001, 21:479.

    Google Scholar 

  18. Mathew NT, Lucker C: Gabapentin in migraine prophylaxis: a preliminary open-label study [abstract]. Neurology 1996, 46:A169.

    Google Scholar 

  19. Nicolodi M, Sicuteri F: An NMDA modulator, Gabapentin, clearly facilitates resolution of chronic migraine. Pharmacol Res 1997, 35(suppl):64.

    Google Scholar 

  20. Mathew NT, Rapoport A, Saper J, et al.: Efficacy of Gabapentin in migraine prophylaxis. Headache 2001, 41:119–128.

    Article  PubMed  CAS  Google Scholar 

  21. Steiner TJ, Findley LJ, Yuen AW: Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997, 17:109–112.

    Article  PubMed  CAS  Google Scholar 

  22. Wheeler SD: Lamotrigine efficacy in migraine prevention. Cephalalgia 2001, 21(4):374.

    Google Scholar 

  23. Lampl C, Buzath A, Klinger D, et al.: Lamotrigine in the prophylactic treatment of migraine aura: a pilot study. Cephalalgia 1999, 19:58–63.

    Article  PubMed  CAS  Google Scholar 

  24. D’Andrea G, Granella F, Cadaldini M, Manzoni GC: Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open-pilot study. Cephalalgia 1999, 19:64–66.

    Article  PubMed  CAS  Google Scholar 

  25. Krusz JC: Lamotrigine as prophylaxis therapy for refractory migraine [poster abstract]. American Headache Society Meeting, Seattle; June, 2002 (in press).

  26. SynerMed Communications: Evolving directions in the management of epilepsy. Clinician 2002, 20:22.

    Google Scholar 

  27. Krusz JC, Scott V, Belanger J: Intravenous propofol: unique effectiveness in treating intractable migraine. Headache 2000, 40:224–230. Recent study that indicates new directions using neuronal stabilizing agents.

    Article  PubMed  CAS  Google Scholar 

  28. Krusz JC, Scott V: Topiramate in the treatment of chronic migraine and other headaches [abstract]. Headache 1999, 39:363.

    Google Scholar 

  29. Storey JT, Calder CS, Potter DL: Potential role of topiramate (TPM) in the treatment of intractable daily headache: a retrospective pilot study. Neurology 1999, 52 (suppl 1):A21.

    Google Scholar 

  30. Storey JR, Calder CS, Potter DL: Role of topiramate for refractory migraine prophylaxis: a retrospective pilot study. Ann Neurol 1999, 46:495.

    Google Scholar 

  31. Shuaib A, Ahmed E, Kochanski P, et al.: Efficacy of topiramate in prophylaxis of frequent severe migraines of chronic daily headaches: experience with 70 patients over 18 months. Cephalalgia 2000, 20:423.

    Google Scholar 

  32. Von Seggern R, Mannix L, Adelman J: Efficacy of topiramate in migraine prophylaxis: a retrospective chart analysis, Neurology 2000, 54(suppl 3):A267-A268.

    Google Scholar 

  33. Potter D, Hart D, Calder C, Storey J: A double-blind, randomized, placebo-controlled study of topiramate in the prophylactic treatment of migraines with or without aura, Cephalalgia 2000, 20:305.

    Article  Google Scholar 

  34. Edwards K, Glantz M, Shea P, Norton J: A double-blind, randomized trial of topiramate versus placebo in the prophylactic treatment of migraine headaches with and without aura. Headache 2000, 40:407.

    Google Scholar 

  35. Krusz JC, Belanger J, Scott VB: Tiagabine in the treatment of very refractory migraines and other headaches. Headache 1999, 39:365.

    Google Scholar 

  36. Freitag FG, Diamond S, Diamond ML, et al.: An open-use trial of Tiagabine in migraine. Headache Q 2000, 11:133–134.

    Google Scholar 

  37. Wong IC, Lhatoo SD: Adverse reactions to new anticonvulsant drugs. Drug Safety 2000, 23:35–56.

    Article  PubMed  CAS  Google Scholar 

  38. Krusz JC, Nett RB: Oxcarbazepine (Trileptal) as prophylaxis for refractory migraines [abstract]. In International Migraine Trust. London; 2000.

  39. Krusz JC: Levetiracetam (Keppra TM) as prophylaxis for resistant headaches. Headache Q 2000, 12:5A.

    Google Scholar 

  40. Krusz JC: Levetiracetam as prophylaxis for resistant headaches. Cephalalgia 2001, 21:373.

    Google Scholar 

  41. Krusz JC: Levetiracetam (Keppra): novel agent for refractory chronic neuropathic pain. J Neurologic Sci 2001, 187:S474.

    Google Scholar 

  42. Krusz JC: Levetiracetam, given intravenously, to treat refractory migraines. Presented at the 14th International Migraine Trust Meeting. London, United Kingdom; September 23–26, 2002. Indicates new directions using neuronal stabilizing agents.

  43. Krusz JC: Zonisamide in the treatment of headache and pain disorders. J Neurologic Sci 2001, 187:S107.

    Article  Google Scholar 

  44. Wagstaff AJ, Bryson HM: Tizanidine: a review of its pharmacology, clinical efficacy, and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs 1997, 53:435–452.

    Article  PubMed  CAS  Google Scholar 

  45. Sakuda M: Clinical effect of tizanidine in muscle contraction headache: improvements of clinical profile, electromyogram, and intramuscular blood flow. Shinryo Shinyaku 1990, 27:1937–1942.

    Google Scholar 

  46. Sakuda M, Takeda K: Beneficial effects of tizanidine on the ischemic muscle contraction in chronic muscle contraction headache. Cephalalgia 1991, 11(suppl 11):339–340.

    Google Scholar 

  47. Fogelholm R, Murros K: Tizanidine in tension-type headache: a placebo-controlled, double-blind, crossover study. Headache 1992, 32:509–513.

    Article  PubMed  CAS  Google Scholar 

  48. D’Alessandro R, Granella F: Tizanidine for chronic cluster headache [letter]. Arch Neurol 1996, 53:1093.

    PubMed  CAS  Google Scholar 

  49. Krusz JC, Belanger J, Mills C: Tizanidine: a novel effective agent for the treatment of chronic headaches. Headache Q 2000, 11:41–45.

    Google Scholar 

  50. Freitag FG, Diamond S, Diamond ML, Urban GJ: Tizanidine HCl in the preventive treatment of chronic tension-type headache. Headache Q 2000, 11:283–285.

    Google Scholar 

  51. Saper JR, Lake AE III, Cantrell DT, et al.: Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study. Headache 2002, 42:470–482.

    Article  PubMed  Google Scholar 

  52. Saper JR, Winner PK, Lake AE III: An open-label dose-titration of the efficacy and tolerability of tizanidine hydrochloride tablets in the prophylaxis of chronic daily headache. Headache 2001, 41:357–368.

    Article  PubMed  CAS  Google Scholar 

  53. Adelman LC, Adelman JU, Von Seggern R, Mannix LK. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 2000, 40:572–580.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Anodyne Pain Care, 5446 Glen Lakes Drive, 75231, Dallas, TX, USA

    John Claude Krusz PhD, MD

Authors
  1. John Claude Krusz PhD, MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krusz, J.C. Prophylaxis for chronic daily headache and chronic migraine with neuronal stabilizing agents. Current Science Inc 6, 480–485 (2002). https://doi.org/10.1007/s11916-002-0067-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-002-0067-9

Keywords

Search

Navigation